17 results about "GLUT4" patented technology

The invention relates to the technical field of biological medicines, in particular to a polypeptide for regulating the activity of a GLUT4 receptor and a medicine application of the polypeptide, the polypeptide comprises SEQ. NO: 1: Asp-Pro-Gly-Leu-Thr (DPGLT), SEQ. NO: 2: His-Cys-Val-Arg-Asn (HCVRN), SEQ. NO: 3: Gly-Met-Ser-Lys-Phe (GMSKF), and SEQ. NO: 4: Tyr-Trp-Arg-His-Glu (YWRHE). The invention also relates to a preparation method of the polypeptide for regulating the activity of the GLUT4 receptor. Experimental results show that the novel polypeptide can effectively promote the transport and activity of GLUT4, improve blood sugar control and reduce the blood sugar level.

The present invention relates to the field of pharmaceuticals and health food technology, and specifically to a method for preparing and applying red date polysaccharides. The specific technical solution comprises the following steps: a method for preparing red date polysaccharides comprises concentrating jujubes with distilled water, removing proteins, and then precipitating with ethanol to obtain a primary ethanol precipitate containing polysaccharides; dialyzing the primary ethanol precipitate, and then precipitating with ethanol to obtain a secondary ethanol precipitate containing polysaccharides, which is then freeze-dried. The extracted red date polysaccharides can improve glucose utilization, increase GLUT4 protein expression, and prevent palmitate-induced insulin resistance and muscle damage in muscle cells, and can be used to prevent, improve, or treat anabolic or muscular diseases.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention provides a method for detecting insulin sensitivity, which comprises the following steps: (1) transfecting a cell to be detected by using a GLUT4myc cDNA plasmid: transfecting the cell to be detected by using the GLUT4myc cDNA plasmid, so that the cell stably expresses GLUT4myc; (2) measuring the endocytosis rate of the GLUT4myc: performing endocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody to be endocytosed, and regularly detecting the amount of the GLUT4myc combined with the anti-myc antibody remained on the surface of the cell; (3) measuring the GLUT4myc exocytosis rate: performing exocytosis stimulation to enable the GLUT4myc combined with the anti-myc antibody in the cell to exocytosis, and regularly detecting the translocation amount of the GLUT4myc combined with the anti-myc antibody in the cell to the surface of the cell; (4) calculating the difference value between the GLUT4myc exocytosis rate and the GLUT4myc endocytosis rate, and calculating the insulin sensitivity according to the difference value; the insulin sensitivity evaluation method has the beneficial effects that the insulin sensitivity is evaluated by detecting the exocytosis and endocytosis rates of fat cells, muscle cells or peripheral blood lymphocytes GLUT4, so that early-stage diabetic patients can be identified, and the pathogenesis of diabetes mellitus can be researched.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

The invention provides application of a stevia rebaudiana extract, and belongs to the technical field of pure natural plant extracts, the stevia rebaudiana extract at least contains phenols, flavones and potassium ions, and when a health care product and / or a composition are given to a subject, at least one of the following components is achieved: antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity and the like. The expression of IRS protein, tyrosine phosphorylation of IRS and the content of GLUT4 protein are increased; bacteria are inhibited, and viruses and allergy are resisted; the intraocular pressure is reduced; the appetite is promoted; the hair loss is prevented or the hair growth is promoted. The application comprises application of the stevia rebaudiana extract in preparation of hair loss preventing or hair growth promoting products. The health-care product containing the stevia rebaudiana extract can prevent or treat type 2 diabetes mellitus, inhibit bacteria or resist viruses or allergy, and can be used as auxiliary food and / or sports food for sub-health people, type 2 diabetes mellitus patients, patients receiving glaucoma treatment, cancer patients, hepatitis patients, overweight people, picky and anorexia children or patients during general disease rehabilitation. The hair loss can be prevented or the hair growth is promoted.

The invention discloses a preparation method of a medicinal and edible plant composition with a synergistic hypoglycemic effect, and relates to the technical field of preparation of medicinal and edible health products. The method comprises the following steps: step a, crushing jerusalem artichoke, bitter gourd and Chinese waxgourd peel according to a mass ratio of 1: (0.5-2): (0.5-1.5) until the particle size is 0.2-0.5 mm, performing cold soaking at 4-10 DEG C for 48-72 hours, and performing filtering to obtain a water-soluble component filtrate; step b, adding cellulase (the enzyme activity is greater than or equal to 10000 U / g) which accounts for 0.1-0.3% of the mass of the raw materials into the residues in the step a; according to the method, multi-process combined extraction is carried out, specifically, heat-sensitive components such as momordica saponins are reserved through cold extraction (4-10 DEG C), fat-soluble components are extracted through supercritical extraction, cell membranes are damaged through high-temperature transduction to release cinnamyl aldehyde, the synanthrin decomposition rate reaches 75% through the enzymolysis technology, the quercetin conversion rate is larger than or equal to 90%, and the quercetin content is larger than or equal to 30% through the enzymolysis technology. According to the invention, four mechanisms, namely alpha-glycosidase inhibition, insulin sensitization, oxidation resistance and GLUT4 transport promotion, are used for synergistically reducing blood glucose, the blood glucose reducing effect is remarkable, the absorption rate of fat-soluble components is increased by 2 times by the nano-emulsion, and the in-vivo half-life period of the balsam pear saponin is prolonged to 6.5 hours by the lipidosome.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of the FER1L6 gene in the prevention and treatment of diabetes. In this application, the expression of GLUT4 is increased by inhibiting the expression of FER1L6, thereby improving the related physiological metabolism in diabetic organisms. This physiological metabolism includes glucose uptake, lipid metabolism, and oxidative stress damage. Experimental results show that FER1L6 is highly expressed in type 2 diabetic mice and insulin-resistant HepG2 cells; reducing FER1L6 expression significantly increases GLUT4 expression, ultimately improving lipid metabolism and oxidative stress damage in diabetic mice, while also enhancing cellular glucose uptake. Therefore, it can be concluded that FER1L6 is a good regulatory target for the prevention and treatment of type 2 diabetes based on the GLUT4 pathway. Based on this target, new technical approaches can be provided for the prevention and control of type 2 diabetes.

The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine compound preparation based on an IR model signal channel and a preparation method of the traditional Chinese medicine compound preparation. 10%-15% of rheum officinale; 15%-20% of mulberry leaves; 20%-30% of radix puerariae; 10%-15% of bitter gourd; 5%-10% of fresh ginger; 5%-10% of cinnamon; according to the traditional Chinese medicine compound preparation, an I RS-GSK3beta-GLUT4 signal channel is regulated and controlled through a specific mechanism so as to improve insulin resistance. By optimizing the ratio of the medicinal materials, the regulating effect on an IR model signal channel is remarkably enhanced, the insulin sensitivity is improved, and meanwhile, the continuous and stable release of the drug effect is realized, so that a more effective solution is provided for the comprehensive treatment of the type 2 diabetes mellitus.

Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and / or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).

The application discloses a kind of flavonoids with the synergistic effect of reducing sugar and its preparation method and application, belong to functional food and microbial technology field.The synbiotic comprises plant lactobacillus N107 live bacteria and rhizoma polygonati polysaccharide ferment, and the ferment is prepared from the crude polysaccharide of raw rhizoma polygonati fermented by homologous bacteria under optimized conditions.After fermentation, the molecular weight of polysaccharide is reduced by more than 70%, the reducing sugar is significantly improved, and butyric acid is produced.In vitro hypoglycemic activity analysis shows that the synbiotic can significantly inhibit alpha-glucosidase activity;Cell experiment shows that it can significantly improve the glucose uptake rate of insulin-resistant HepG2 cells;Mechanically, it inhibits gluconeogenesis and promotes Glut4 translocation through PI3K / Akt / FoxO1 pathway.The present application directly uses raw rhizoma polygonati polysaccharide, avoids degradation by cooking, realizes green biotransformation of polysaccharide and synergistic hypoglycemic effect of synbiotic, has the advantages of probiotics and prebiotics, and the polysaccharide utilization rate is high.

The invention discloses a classification method for verifying burden-reducing and transsaccharide hypoglycemic drugs, and belongs to the technical field of drug relationship classification, male mice are selected, are freely fed with common feed and then are replaced with high-fat feed, STZ injection is carried out, then the mice are selected and grouped, and the drug administration volume is adjusted according to the body weight; metabolism cage detection, OGTT / IRT and dynamic blood glucose detection are carried out alternately; carrying out sample collection according to a sequence of heart, kidney, liver, quadriceps femoris muscle, aorta and pancreas; establishing a database for data analysis; detecting a tissue morphological structure, a kidney SGLT2 protein expression quantity, a liver glycogen content and muscle GLUT4 membrane translocation efficiency; detecting the sensitivity of serum beta-hydroxybutyric acid (ketone body) and insulin; and pathological analysis is carried out through aorta oil red O and pancreas beta cell morphological staining. According to the method, a'burden-reducing type-transsaccharide 'classification standard based on a physiological mechanism is created for the first time, the problem that traditional chemical structure / target point classification is disjointed with drug effects is solved, and the classification accuracy reaches 92.3% (n is equal to 60 animal verification).

The present invention is directed to, inter alia, therapeutic compositions comprising therapeutically effective amount of exosomes derived from cells having increased glucose transporter type 4 (GLUT4) activity, and a pharmaceutically acceptable. The invention is further directed to methods for reducing glucose levels in a subject in need thereof.

The invention discloses an application of malic acid in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that malic acid can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; malic acid can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; the malic acid is used for activating a PI3K / AKT signal channel to up-regulate the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulate the expression of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the malic acid has a protection or repair effect on liver injury.

The invention discloses an amaranthus hypochondriacus extract based on solid state fermentation of rhizopus oligosporus as well as a fermentation method and application of the amaranthus hypochondriacus extract. According to the invention, rhizopus oligosporus is utilized to carry out solid state fermentation on grain amaranth, and then ethanol is utilized to carry out ultrasonic-assisted extraction, so that the obtained grain amaranth extract has the capability of improving insulin resistance. Experiments prove that the amaranthus hypochondriacus extract can improve insulin resistance of HepG2 and 3T3-L1 cells through IRS-1 / PI3K / Akt / GLUT4 and PPAR gamma / C-EBP alpha / GLUT4 pathways, and compared with an unfermented sample, an oil phase sample obtained after solid state fermentation of rhizopus oligosporus for 3 days has a better effect. The invention provides an important theoretical basis for the amaranthus hypochondriacus in preparation of drugs for regulating insulin resistance.

The invention provides an application of a dandelion water extract in preparation of a composition for improving muscle mass and skin moisture content, the dandelion water extract is obtained by extracting dandelion with a solvent, and the solvent is water. The dandelion water extract is further used for reducing the expression quantity of PPARG2 gene, C / EBP-alpha gene and GLUT4 gene and increasing the expression quantity of UCP1 gene and CETP gene so as to achieve the effects of reducing fat accumulation, promoting cholesterol metabolism, increasing muscle mass and promoting aquaporin generation.

The invention discloses application of dauricine in preparation of a medicine for treating diabetes mellitus, and belongs to the technical field of biological medicine. Preliminary drug screening shows that dauricine has hypoglycemic activity. Further experiments prove that dauricine has the influence on glucose uptake of L6 cells, transfer of GLUT4 and the like. In addition, the correlation between dauricine and Ca < 2 + > is also proved. The invention provides a theoretical basis for research and development of dauricine for treating type 2 diabetes mellitus.